Medicines Co. jumps on rumors of a multibillion-dollar buyout

Damian Garde Drugmaker the Medicines Company saw its shares rise as high as 14% on rumors that the company may be up for sale. FierceBiotech News

Who are the most influential people in biopharma today?

Damian Garde We'd like you to weigh in on how that certain R&D executive is blazing a trail, why a particular regulator is changing how drugmakers do business, or how one CEO ...

Pfizer expands consumer biz in China with Treerly supplements buy

Tracy Staton Pfizer's consumer health unit is said to be destined for sale, but that doesn't mean the business has stopped making its own buys. The drug giant snapped up ...

NIH and HHS get ‘march-in’ request for Astellas’ Xtandi

Emily Wasserman Less than a week after lawmakers asked the National Institutes of Health (NIH) and the U.S. Department of Health and Human Services (HHS) to take "extraordinary" ...

Depomed isn’t anti-takeover, CEO says. It was just anti-Horizon

Carly Helfand SAN FRANCISCO–Let Depomed be clear: it may not have been too keen on Horizon Pharma's buyout offer from last year, but that doesn't mean it's opposed ...

Pfizer CEO: Allergan deal is ‘a lot more about growth’ than job cuts

Carly Helfand Anyone who's examined Pfizer's job-chopping track record knows the company has a tendency to wield the ax in the wake of a megamerger. But this time? Things will ...

#JPM16 Roundup: What you need to know on Pfizer, Sanofi and more

Carly Helfand SAN FRANCISCO–On Monday, we brought you the lowdown from the J.P. Morgan Healthcare Conference, with company presentations from pharma giants including Novartis ...

Novartis kicks it into high gear to revive flailing Alcon unit

Emily Wasserman Novartis' Alcon business has been struggling for some time now, and the company's efforts to help its eye-care business get back on track don't seem to be ...

Much-hyped Moderna barrels into the clinic with 6 human trials planned for ’16

Damian Garde Moderna Therapeutics, a superlatively well-funded private biotech, has made the leap from preclinical bluster to first-in-human trials, testing out its inaugural candidate ...

Pricing pressure: Doubling down on the political drama

John Carroll ​With all the brouhaha over Martin Shkreli's 5000%-plus price hike, it's important to remember what got us to this point on drug pricing and where we're left ...

The top biopharma trends for 2016

John Carroll Look back on 2015 and you'll see an industry that has come into its own. With billions of dollars flowing in from IPOs, follow-ons, venture investors, the rich (those ...

Valeant strikes price-cutting deal with Walgreens, hoping to polish its tarnished image

Carly Helfand Valeant has been pummeled recently by drug pricing pushback, antitrust allegations and investigations into its business practices. But now, it has a new deal in hand that ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS